buprenorphine

(redirected from Butrans)
Also found in: Medical.

bu·pre·nor·phine

 (byo͞o′prə-nôr′fēn′)
n.
A semisynthetic opioid drug, C29H41NO4, used usually in its hydrochloride form as an analgesic and, in combination with naloxone, for long-term treatment of addiction to opioids such as heroin.

[bu(tyl) + pr(opyl) + en(do-) or (eth)en(e) + (m)orphine.]

buprenorphine

(bjuːˈprɛnɔːfiːn)
n
(Medicine) an opiate used medicinally as a powerful analgesic
Translations

buprenorphine

n buprenorfina
Mentioned in ?
References in periodicals archive ?
They also took noncontrolled drugs including Butrans which are used for pain relief and psychostimulants for treatment of conditions such as ADHD.
Extended-Release and Long-Acting Opioid Analgesics Requiring a Risk Evaluation and Mitigation Strategy Buprenorphine (Butrans) Fentanyl transdermal system (Duragesic) Hydromorphone hydrochloride (Exalgo) Methadone hydrochloride (Dolophine) Morphine sulfate (Avinza, MS Contin, Kadian) Morphine sulfate and naltrexone hydrochloride (Embeda) Oxycodone hydrochloride controlled-release (OxyContin) Oxymorphone hydrochloride (Opana ER) Oxymorphone hydrochloride Extended-Release (Opana ER) Tapentadol (Nucynta ER) Note.
Boca Raton, FL, June 30, 2013 --(PR.com)-- American Clinical Solutions is going to launch a new testing service for BuTrans (buprenorphine) in urine samples soon.
The buprenorphine patch (Butrans) is a promising new patch that is only a partial opioid agonist and seems to both be effective in fibromyalgia and have less association with opioidinduced hyperalgesia.
(127) For example, the FDA approved Butrans (buprenorphine), an opioid administered through a patch placed on the patient's skin for managing moderate to severe chronic pain.
Transdermal buprenorphine (Butrans) was approved by the Food and Drug Administration in June 2010 for management of chronic pain in adults, said Dr.
Oramorph, oxycodone (OxyContin), hydromorphone (Exalgo), transdermal fentanyl (Duragesic), buprenorphine (Butrans), and oxymorphone (Opana ER).
In 2010, the FDA approved Butrans, an extended-release buprenorphine patch (Purdue Pharma), in 5-, 10- and 20-mcg/hour doses.